Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children (COG AALL1731)

Phase 3 trial of children with newly diagnosed standard-risk B-cell ALL at average or higher risk of relapse, randomized to chemotherapy alone (n=722) or chemotherapy plus two nonsequential 28-day blinatumomab cycles (n=718). Interim analysis led to early termination of randomization. At median follow-up 2.5 years, estimated 3-year DFS was 96.0±1.2% vs 87.9±2.1% (P<0.001). Among average-risk: 97.5±1.3% vs 90.2±2.3%; among higher-risk: 94.1±2.5% vs 84.8±3.8%. Level 1 (randomized; MRD contributes to COG risk groups).

N Engl J MedPubMed 39651791